专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006121831A3 HIV INTEGRASE INHIBITORS 审中-公开
标题翻译：艾滋病毒整合抑制剂
公开(公告)号：WO2006121831A3
公开(公告)日：2007-10-25
申请号：PCT/US2006017369
申请日：2006-05-05
申请人： MERCK & CO INC , VACCA JOSEPH P , WAI JOHN S , PAYNE LINDA S , ISAACS RICHARD C A , HAN WEI , EGBERTSON MELISSA , PRACITTO RICHARD
发明人： VACCA JOSEPH P , WAI JOHN S , PAYNE LINDA S , ISAACS RICHARD C A , HAN WEI , EGBERTSON MELISSA , PRACITTO RICHARD
IPC分类号： A61K31/40 , A61K31/445
CPC分类号： C07D471/14 , A61K31/4353 , A61K31/4375 , C07D498/14
摘要： Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R l , R 2 and R 3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
摘要翻译：式（I）的三环化合物是HIV整合酶和HIV复制抑制剂的抑制剂：其中键合a，环A，R 1，R 2和R 3 在本文中定义。该化合物可用于预防或治疗艾滋病毒感染以及艾滋病的预防，治疗或延迟。这些化合物被用作抗HIV感染和艾滋病作为化合物本身或以药学上可接受的盐的形式。化合物及其盐可以用作药物组合物中的成分，任选与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合使用。

2. 发明申请

WO03077857A2 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS 审中-公开
标题翻译：用作HIV整合酶抑制剂的N-（取代苄基）-8-羟基-1,6-萘啶-7-羧酰胺
公开(公告)号：WO03077857A2
公开(公告)日：2003-09-25
申请号：PCT/US0307671
申请日：2003-03-12
申请人： MERCK & CO INC , EGBERTSON MELISSA , LANGFORD H MARIE , MELAMED JEFFREY Y , WAI JOHN S , HAN WEI , PERLOW DEBBIE S , ZHUANG LINGHANG , EMBREY MARK , YOUNG STEVEN D
发明人： EGBERTSON MELISSA , LANGFORD H MARIE , MELAMED JEFFREY Y , WAI JOHN S , HAN WEI , PERLOW DEBBIE S , ZHUANG LINGHANG , EMBREY MARK , YOUNG STEVEN D
IPC分类号： A61K31/4375 , A61K31/541 , A61K31/549 , A61K45/00 , A61P31/18 , A61P43/00 , C07D471/02 , C07D471/04 , A61K
CPC分类号： C07D471/04
摘要： N-(Substituted benzyl)-8-hydroxy- 1,6-naphthyridine-7-carboxamides are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the naphthyridine carboxamides are of Formula (II): (II),wherein R1', R2' and R3' are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are described.
摘要翻译： N-（取代的苄基）-8-羟基-1,6-萘啶-7-甲酰胺是HIV整合酶和HIV复制抑制剂的抑制剂。在一个实施方案中，萘啶甲酰胺具有式（II）：（II），其中R 1'，R 2'和R 3'在本文中定义。这些化合物可用于预防和治疗艾滋病毒感染以及预防，延迟艾滋病的发病和治疗。这些化合物被用作抗HIV感染和艾滋病作为化合物本身或以药学上可接受的盐的形式。化合物及其盐可以用作药物组合物中的成分，任选与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合使用。描述了预防，治疗或延缓AIDS发病的方法以及预防或治疗HIV感染的方法。

3. 发明申请

WO2004083173A3 KETOPIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS 审中-公开
标题翻译：作为布拉霉素拮抗剂的酮替丁衍生物
公开(公告)号：WO2004083173A3
公开(公告)日：2005-03-03
申请号：PCT/US2004007942
申请日：2004-03-15
申请人： MERCK & CO INC , BOCK MARK , DORSEY BRUCE , SU DAI-SHI , HAN WEI , WOOD MICHAEL
发明人： BOCK MARK , DORSEY BRUCE , SU DAI-SHI , HAN WEI , WOOD MICHAEL
IPC分类号： A61K31/495 , A61K31/496 , A61K31/5377 , C07D20060101 , C07D241/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12
CPC分类号： C07D403/12 , C07D241/08 , C07D401/12 , C07D401/14 , C07D403/14 , C07D413/12
摘要： Ketopiperazine derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
摘要翻译：酮哌嗪衍生物是可用于治疗或预防与缓激肽B1途径相关的疼痛和炎症等症状的缓激肽B1拮抗剂或反向激动剂。

4. 发明申请

WO02099388A3 BENZODIAZEPINE BRADYKININ ANTAGONISTS 审中-公开
公开(公告)号：WO02099388A3
公开(公告)日：2003-05-01
申请号：PCT/US0221065
申请日：2002-06-03
申请人： MERCK & CO INC , WOOD MICHAEL R , BOCK MARK G , SU DAI-SHI , KUDUK SCOTT D , HAN WEI , DORSEY BRUCE D
发明人： WOOD MICHAEL R , BOCK MARK G , SU DAI-SHI , KUDUK SCOTT D , HAN WEI , DORSEY BRUCE D
IPC分类号： A61P19/00 , A61P29/00 , C07D243/14 , C07D243/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/04 , A61K31/55 , C07D243/00
CPC分类号： C07D401/12 , C07D243/14 , C07D243/24 , C07D401/14 , C07D403/12 , C07D417/12 , C07D471/04
摘要： Compounds disclosed here or a pharmaceutically acceptable salt thereof, are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
摘要翻译：本文公开的化合物或其药学上可接受的盐是可用于治疗或预防与缓激肽B1途径相关的疼痛和炎症等症状的缓激肽B1拮抗剂化合物。

5. 发明申请

WO2007070816A3 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS 审中-公开
标题翻译：噻吩衍生物作为因子XIA抑制剂
公开(公告)号：WO2007070816A3
公开(公告)日：2007-09-07
申请号：PCT/US2006061970
申请日：2006-12-13
申请人： SQUIBB BRISTOL MYERS CO , HAN WEI
发明人： HAN WEI
IPC分类号： C07D333/24 , A61K31/381 , A61K31/416 , A61P7/02 , A61P29/00 , C07D333/28 , C07D409/04
CPC分类号： C07D333/24 , C07D333/28 , C07D409/04
摘要： The present invention provides compounds of Formula (I); or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, L 1 , R 3 , and R 11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译：本发明提供了式（I）的化合物; 或其立体异构体，互变异构体，可药用盐，溶剂化物或前药，其中变量A，L 1，R 3，R 11，如本文所定义。式（I）化合物可用作凝血级联和/或接触活化系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。具体而言，它涉及选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用该组合物治疗血栓栓塞性和/或炎症性疾病的方法。

6. 发明申请

WO2004037176A3 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS 审中-公开
标题翻译：喹唑啉酮及其衍生物作为因子XA抑制剂
公开(公告)号：WO2004037176A3
公开(公告)日：2004-10-14
申请号：PCT/US0332816
申请日：2003-10-16
申请人： SQUIBB BRISTOL MYERS CO , HAN WEI , HU ZILUN
发明人： HAN WEI , HU ZILUN
IPC分类号： C07D239/91 , C07D401/04 , C07D401/10 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/14 , A61K31/505 , C07D239/70
CPC分类号： C07D401/14 , C07D239/91 , C07D401/04 , C07D401/10 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/14
摘要： The present application describes quinazolinones and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
摘要翻译：本申请描述了可用作因子Xa抑制剂的喹唑啉酮及其衍生物或其药学上可接受的盐形式。

7. 发明申请

WO2004098508A3 METHODS FOR PRODUCTION OF NON-DISEASE CAUSING HEMOGLOBIN BY EX VIVO OLIGONUCLEOTIDE GENE EDITING OF HUMAN STEM/PROGENITOR CELLS 审中-公开
标题翻译：用于通过人血清/原核细胞的体外寡核苷酸基因编码产生非病毒的非病毒的方法
公开(公告)号：WO2004098508A3
公开(公告)日：2005-03-31
申请号：PCT/US2004013404
申请日：2004-04-30
申请人： NAPRO BIOTHERAPEUTICS INC , HAN WEI , CHOMO MATTHEW J , WONG MARGARET , FISH BARBARA H , IRELAND CAROLYN M , BEHRENS DAVETTE L
发明人： HAN WEI , CHOMO MATTHEW J , WONG MARGARET , FISH BARBARA H , IRELAND CAROLYN M , BEHRENS DAVETTE L
IPC分类号： A01K67/027 , A61K20060101 , A61K48/00 , C12N15/85
CPC分类号： A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0306
摘要： Methods are presented for applying ex vivo oligonucleotide gene editing to hematopoietic stem cells and/or progenitor cells to create therapeutically effective amounts of wild-type hemoglobin for treatment of the hemoglobinopathies.
摘要翻译：提出了将离体寡核苷酸基因编辑应用于造血干细胞和/或祖细胞以产生用于治疗血红蛋白病的治疗有效量的野生型血红蛋白的方法。

8. 发明申请

WO2011150883A3 METHOD AND DEVICE FOR TERMINAL BATCH UPGRADING 审中-公开
标题翻译：用于终端批量升级的方法和装置
公开(公告)号：WO2011150883A3
公开(公告)日：2012-05-24
申请号：PCT/CN2011076199
申请日：2011-06-23
申请人： HUAWEI DEVICE CO LTD , WANG JING , HAN WEI , DONG NIAN , ZHU GUANGZE
发明人： WANG JING , HAN WEI , DONG NIAN , ZHU GUANGZE
IPC分类号： H04L12/24 , H04L29/06 , H04L29/12
CPC分类号： H04L41/082
摘要： The embodiments of the present invention disclose a method and device for terminal batch upgrading. The method includes: assigning different Internet Protocol (IP) addresses to different virtual network cards communicating with various terminals; binding respectively upgrade data packets, needing to be transmitted, with the various virtual network cards, or transmitting respectively maintenance IP address modification commands to the terminals communicating with the various virtual network cards, so that each terminal can modify its own maintenance IP address to a preset IP address separately, wherein the modified preset IP addresses of the various terminals are different; transmitting the upgrade data packets simultaneously to the various terminals via the different IP addresses of the various virtual network cards, so that the various terminals can fulfill the upgrading after receiving the upgrade data packets.
摘要翻译：本发明的实施例公开了一种用于终端批量升级的方法和装置。该方法包括：向与各种终端通信的不同虚拟网卡分配不同的因特网协议（IP）地址; 绑定分别升级需要与各种虚拟网卡进行传输的数据包，或者分别向与各种虚拟网卡通信的终端发送维护IP地址修改命令，以便每个终端可以将其自己的维护IP地址修改为预设IP地址，其中各个终端的修改的预设IP地址不同; 通过各种虚拟网卡的不同IP地址将升级数据包同时发送到各个终端，使得各种终端可以在接收到升级数据包之后实现升级。

9. 发明申请

WO2004031145A3 LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS 审中-公开
标题翻译：含有LAMAM的二氨基甲酰胺，β-氨基酸，ALPHA-氨基酸及其作为因子XA抑制剂的衍生物
公开(公告)号：WO2004031145A3
公开(公告)日：2004-07-01
申请号：PCT/US0331079
申请日：2003-10-01
申请人： SQUIBB BRISTOL MYERS CO , QIAO JENNIFER X , HAN WEI
发明人： QIAO JENNIFER X , HAN WEI
IPC分类号： C07D211/76 , C07D213/64 , C07D213/75 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/02 , A61K31/44 , A61K31/445 , C07D211/80
CPC分类号： C07D213/64 , C07D211/76 , C07D213/75 , C07D401/12 , C07D405/12 , C07D409/12
摘要： The present application describes lactam-containing diaminoalkyl, b-aminoacids, a-aminoacids and derivatives thereof of Formula ( I): P-M-M1 or pharmaceutically acceptable salt forms thereof, wherein M is a linear core. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
摘要翻译：本申请描述了式（I）的含有内酰胺的二氨基烷基，β-氨基酸，α-氨基酸及其衍生物：P-M-M1或其药学上可接受的盐形式，其中M是线性核。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa。

10. 发明申请

WO2004041776A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS 审中-公开
标题翻译：磺酰胺戊醇酸酯及其衍生物作为因子Xa抑制剂
公开(公告)号：WO2004041776A2
公开(公告)日：2004-05-21
申请号：PCT/US0314142
申请日：2003-05-05
申请人： SQUIBB BRISTOL MYERS CO , SMALLHEER JOANNE M , PINTO DONALD J , WANG SHUAIGE , QIAO JENNIFER X , HAN WEI , HU ZILIN
发明人： SMALLHEER JOANNE M , PINTO DONALD J , WANG SHUAIGE , QIAO JENNIFER X , HAN WEI , HU ZILIN
IPC分类号： C07D211/76 , C07D401/10 , C07D401/14 , C07D409/14 , C07D417/14 , C07D495/04 , C07D
CPC分类号： C07D409/14 , C07D211/76 , C07D401/10 , C07D401/14 , C07D417/14 , C07D495/04
摘要： The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula (I), or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
摘要翻译：本申请描述了式（I）的磺酰氨基戊内酰胺及其衍生物或其药学上可接受的盐形式，其中环G为单环或双环碳环或杂环。本发明化合物可用作胰蛋白酶样丝氨酸蛋白酶，特别是Xa因子的抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式